Colorcon launches new $50 million VC Fund17 Sep 2019
The fund will target investments in transformational solutions across manufacturing, supply chain, and delivery of pharmaceutical products and services.
Colorcon has established Colorcon Ventures to invest in promising companies in the pharmaceutical industry. Colorcon’s business focus is on advanced coating systems, modified release technologies and functional excipients for use in pharmaceutical immediate and modified release dosage forms.
Colorcon Ventures is a $50 million venture fund focused on startups that are strategically relevant to the core Colorcon business. The fund will target investments in transformational solutions across manufacturing, supply chain, and delivery of pharmaceutical products and services. The fund is not investing in companies developing active ingredients or molecules.
The fund will be stage-agnostic, with an emphasis on early and mid-stage companies that demonstrate product market fit and revenue growth. Colorcon Ventures will invest in startups where Colorcon can add value in the form of subject matter expertise or commercial relationships, and leverage Colorcon’s global reach, relationships within the pharmaceutical industry, and agile R&D approach.
“We are excited to launch this venture fund to support the growth of startup companies in the pharmaceutical and healthcare industries,” said Martti Hedman, CEO of Colorcon. “Colorcon has a rich history of innovation and we believe this fund will allow us to continue to serve our customers by partnering with startups.”
Touchdown Ventures, a firm specializing in corporate venture capital, will help manage the Colorcon Ventures fund. Touchdown will work closely with senior executives of Colorcon in all aspects of operating the fund.
“The promise of corporate venture capital is to bring more than just money to the table. A successful corporate investor can generate meaningful value by facilitating commercial relationships with its portfolio companies. We believe that Colorcon Ventures, through close association to the senior executive and business units of Colorcon, is well poised to accomplish this goal,” said David Horowitz, CEO of Touchdown.
Finalists announced for this year's CPhI Worldwide Awards
17 Oct 2019
The winners’ shortlist is packed with 40 of the industry’s most innovative companies and individuals who are shaping the future of pharma.Read more
Sanofi opens its first digitally-enabled, continuous manufacturing facility
15 Oct 2019
One of the first digital manufacturing facilities in the world to use continuous, intensified biologics production technology.Read more
FDA approves first and only medicine in a new class of acute treatment for migraine
15 Oct 2019
The approval of Eli Lilly's Reyvow represents the first new class of acute migraine treatment approved by the FDA in more than two decades.Read more
Lonza’s Ibex solutions to support Genmab’s growing clinical portfolio
14 Oct 2019
Company's Ibex Design planned to take Genmab’s pre-clinical candidates from gene to potential IND within 12 months.Read more
Funding to accelerate delivery of Univercells' vaccine portfolio
11 Oct 2019
European financing to support Univercells’ R&D investments to develop four essential and undersupplied global health vaccines to be produced at affordable prices, high quality and large volumes.Read more
Industrial-scale manufacture of therapeutic exosomes
10 Oct 2019
Coordinated purification process development service accelerates progress to clinical trials, and scale-up manufacturing.Read more
FUJIFILM Irvine Scientific receives CE mark approval for multiple ART media
9 Oct 2019
Innovative ART products now available in Europe.Read more
Janssen opens new biomanufacturing building in Ireland
8 Oct 2019
Expansion creates 200 new full-time jobs and increases the company’s production capacity by an additional 19,100 m2.Read more
BASF and Biomillenia join forces in microbiome research to promote healthy skin
7 Oct 2019
Research aims to identify novel dermocosmetic active ingredients via unique microbiome-on-a-chip technology.Read more
Allergan expands Refresh eye treatment portfolio
7 Oct 2019
A trifecta of relief formulated with HydroCell technology offers new artificial tear options for patients suffering from eye dryness.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation